Variation of serum PSA levels in male COVID-19 infected patients with benign prostatic hyperplasia (BPH)
Session
Medicine and Nursing
Description
Objective: To investigate the effect of SARS CoV-2 on serum total PSA levels in men with BPH diagnosed with COVID-19.
Methods: PSA levels were measured with Cobas E 411, in patients who had a PSA control at least 3 months, but not more than 6 months, before the diagnosis of acute infection COVID-19, were examined retrospectively. PSA levels were measured and recorded from these patients on the first day of diagnosis of COVID-19. These patients were called back for outpatient urology follow-up at the third month after completion of treatment for COVID-19. PSA levels measured in the period before COVID-19, during the period of active infection with COVID-19 and in the period after COVID-19 were compared.
Results: In total, 31 patients had a serum PSA level of 1.58 +-1.09 ng/ml in the pre-COVID-19 period, a serum PSA level of 4.34 +- 3.78 ng/ml mL measured in the period of COVID-19 and 2.09 +-2.70 ng. /mL in the post-COVID-19 period. It was determined that the serum PSA level measured during active COVID-19 infection was statistically significantly higher than the PSA levels measured according to the period before COVID-19 and the period after COVID-19 (P < .001, P < .001 respectively).
Conclusion: SARS-CoV-2 infection in men diagnosed with BPH causes significant increases in PSA levels during the active period of the disease.
Keywords:
PSA, COVID-19, BPH, prostate.
Proceedings Editor
Edmond Hajrizi
ISBN
978-9951-550-50-5
Location
UBT Kampus, Lipjan
Start Date
29-10-2022 12:00 AM
End Date
30-10-2022 12:00 AM
DOI
10.33107/ubt-ic.2022.164
Recommended Citation
Gashi, Zafer; Zeqiraj, Afrim; Elezaj, Shkelzen; and Gashi, Fitore, "Variation of serum PSA levels in male COVID-19 infected patients with benign prostatic hyperplasia (BPH)" (2022). UBT International Conference. 165.
https://knowledgecenter.ubt-uni.net/conference/2022/all-events/165
Variation of serum PSA levels in male COVID-19 infected patients with benign prostatic hyperplasia (BPH)
UBT Kampus, Lipjan
Objective: To investigate the effect of SARS CoV-2 on serum total PSA levels in men with BPH diagnosed with COVID-19.
Methods: PSA levels were measured with Cobas E 411, in patients who had a PSA control at least 3 months, but not more than 6 months, before the diagnosis of acute infection COVID-19, were examined retrospectively. PSA levels were measured and recorded from these patients on the first day of diagnosis of COVID-19. These patients were called back for outpatient urology follow-up at the third month after completion of treatment for COVID-19. PSA levels measured in the period before COVID-19, during the period of active infection with COVID-19 and in the period after COVID-19 were compared.
Results: In total, 31 patients had a serum PSA level of 1.58 +-1.09 ng/ml in the pre-COVID-19 period, a serum PSA level of 4.34 +- 3.78 ng/ml mL measured in the period of COVID-19 and 2.09 +-2.70 ng. /mL in the post-COVID-19 period. It was determined that the serum PSA level measured during active COVID-19 infection was statistically significantly higher than the PSA levels measured according to the period before COVID-19 and the period after COVID-19 (P < .001, P < .001 respectively).
Conclusion: SARS-CoV-2 infection in men diagnosed with BPH causes significant increases in PSA levels during the active period of the disease.